NeuroSense’s PrimeC shows positive biomarker data from ALS Phase 2b trial

NeuroSense announces positive 12-month iron biomarker data from its Phase IIb study which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis, or ALS. This data provides additional insights that align with the company’s recent announcements of improved survival by 43% and slowed disease progression by 36%. These new results demonstrate the target engagement of PrimeC in iron regulation, which is linked to disease mitigation and improved survival. The 12-month study results show a significant decrease in ferritin levels and a corresponding increase in transferrin levels, both indicating alleviation of the pathology. Iron levels remained stable over the 12-month dosing period. These positive changes in iron metabolism align with improved clinical outcomes. Patients on PrimeC maintained better functionality and survival rates compared to those on placebo. The company is currently compiling additional data to share with the FDA for discussion to determine the clinical and regulatory path forward. Additionally, the company is continuing advanced discussions with several potential development partners to explore marketing opportunities following the potential completion and approval of PrimeC for ALS.